<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494350</url>
  </required_header>
  <id_info>
    <org_study_id>S-10-0006; A-16898.3</org_study_id>
    <nct_id>NCT01494350</nct_id>
  </id_info>
  <brief_title>WR 279,396 Open Label Treatment Protocol in Tunisia</brief_title>
  <official_title>Open-label Treatment of Non-complicated, Non-severe, Cutaneous Leishmaniasis in Tunisia With WR 279,396 (Paromomycin + Gentamicin Topical Cream) )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The U.S. Army has recently completed a Phase 3 clinical trial in Tunisia. This is an
      open-label single site trial designed to expand our safety database and capture additional
      efficacy (final clinical cure rate of an index lesion) of WR 279,396 Topical Cream in
      Tunisian subjects with non-complicated, non-severe Cutaneous Leishmaniasis (CL). Subjects
      will be patients who visit Ministry of Health sponsored clinics in Tunisia who present with
      at least one CL lesion that is ulcerated and amenable to topical treatment. Potential trial
      subjects will be consented and screened for eligibility including medical history, physical
      exam, lesion parasitology, and renal and liver function tests. If eligible for the study,
      subjects will receive WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) (target n
      = 110). The cream will be applied topically to all CL lesions once daily for 20 days by an
      investigator or study nurse. If a subject develops a new lesion during the study, the new
      lesion may also be treated with the topical cream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will have an in-clinic follow-up on Days 28 +/- 2 days, 42 +/- 4 days and 98 +/- 8
      days to assess safety and cure rates. Safety variables including adverse events (AEs) and
      serious adverse events (SAEs) will be collected through Day 98. For the primary efficacy
      evaluation, the index ulcerative lesion will be assessed for clinical response by measurement
      of the length and width of area of ulceration. All other treated lesions will also be
      assessed for cure as secondary efficacy endpoints with ulcerated and non-ulcerated lesions
      being evaluated independently. An ulcerated lesion will be considered to be completely cured
      if 100% reepithelialization is observed. The length and width of non-ulcerated lesions
      (nodules, plaques) will also be measured and evaluated for cure (ie, absence of signs of an
      active lesion). The primary efficacy endpoint is the final clinical cure rate calculated by
      the number of index lesions that had 100% reepithelialization at Day 98 divided by the total
      number of index lesions that received at least one topical treatment of WR 279,396.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was closed prematurely due study team travel restrictions.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Clinical Cure Rate for the Index Lesion</measure>
    <time_frame>Final clincial cure is measured at day 98</time_frame>
    <description>Number of index lesions with 100% reepithelialization at Day 98.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area of Index Lesions Throughout the Study</measure>
    <time_frame>Measured at day 0, 20, 28, 42, and 98</time_frame>
    <description>Area (mm^2) of index lesion on Days 0, 20, 28, 42, and 98.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Index Lesions With Reepithelialization Throughout the Study</measure>
    <time_frame>Measured at day 28 and 42</time_frame>
    <description>Number of index lesions with 100% reepithelialization on Days 28 and 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of All Ulcerated Lesions Throughout the Study</measure>
    <time_frame>Measured at day 20, 28, 42 and 98</time_frame>
    <description>Area of all ulcerated lesions on Days 20, 28, 42, and 98.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Ulcerated Lesions With Reepithelialization on Day 28</measure>
    <time_frame>Measured on day 28</time_frame>
    <description>Final cure rate for all ulcerated lesions (100% reepithelialization for ulcerative lesions) on Day 28</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>WR 279,396 topical cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WR 279,396 topical cream</intervention_name>
    <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
    <arm_group_label>WR 279,396 topical cream</arm_group_label>
    <other_name>WR 279, 396</other_name>
    <other_name>Topical Paromomycin + Gentamicin Cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Subject has a diagnosis of CL in at least one lesion by at least one of the following
             methods: 1) microscopic identification of amastigotes in stained lesion tissue, or 2)
             positive culture for promastigotes.

          -  Subject has a parasitologically confirmed lesion that satisfies the following criteria
             for an Index lesion:

               -  ulcerative in character

               -  lesion size ≥ 1 cm and ≤5 cm (including the area of induration surrounding the
                  lesion)

               -  not located on the ear, or on a location that in the opinion of the PI is
                  difficult to maintain application of study drug topically.

          -  Subject has &lt; 7 leishmaniasis total lesions.

          -  Subject is willing to forego other forms of treatments for CL including other
             investigational treatments during the study.

          -  In the opinion of the investigator, the subject (or their legal guardian) is capable
             of understanding and complying with the protocol.

        Exclusion Criteria:

          -  Female with a positive serum pregnancy test or who is breast feeding.

          -  History of clinically significant medical problems in the investigator's judgment that
             might interact, either negatively or positively, with topical treatment of
             leishmaniasis including any immunocompromising condition.

          -  Age adjusted blood creatinine or blood urea nitrogen (BUN) levels indicative of
             clinically significant renal disease or aspartate amino transferase (AST), alanine
             amino transferase (ALT), or total bilirubin that suggest clinically significant
             hepatic impairment as judged by the PI or subinvestigator. Note: This study is
             designed to evaluate populations who may have some renal or hepatic dysfunction as the
             drug has not been shown to have serum levels that would be expected to show renal or
             hepatic toxicity and treatment of the general population presenting with CL is highly
             desired based on its safety profile compared to other leishmanial drugs.

          -  Evidence of disseminated leishmaniasis.

          -  Received treatment for leishmaniasis with antimonials or any medication likely, in the
             opinion of the PI, to modify the course of the Leishmania infection within 56 days of
             starting study treatments.

          -  History of known or suspected hypersensitivity or idiosyncratic reactions to
             aminoglycosides.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afif Ben Salah, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Pasteur Tunisia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Clinic-Sidi Bouzid</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2014</results_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cutaneous leishmaniasis</keyword>
  <keyword>topical treatment</keyword>
  <keyword>Tunisia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>184 total screened and there were 134 screen failures.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>WR 279,396 Topical Cream</title>
          <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Worsening of lesion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>modified intent to treat (mITT)/safety subjects</population>
      <group_list>
        <group group_id="B1">
          <title>WR 279,396 Topical Cream</title>
          <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of lesions per subject</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.96" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Final Clinical Cure Rate for the Index Lesion</title>
        <description>Number of index lesions with 100% reepithelialization at Day 98.</description>
        <time_frame>Final clincial cure is measured at day 98</time_frame>
        <population>modified intent to treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396 Topical Cream</title>
            <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Clinical Cure Rate for the Index Lesion</title>
          <description>Number of index lesions with 100% reepithelialization at Day 98.</description>
          <population>modified intent to treat (mITT)</population>
          <units>lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>index lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of Index Lesions Throughout the Study</title>
        <description>Area (mm^2) of index lesion on Days 0, 20, 28, 42, and 98.</description>
        <time_frame>Measured at day 0, 20, 28, 42, and 98</time_frame>
        <population>modified intent to treat (mITT). Baseline for this outcome measure does not include one subject (1 index lesion) who withdrew on Day 18.</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396 Topical Cream</title>
            <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
          </group>
        </group_list>
        <measure>
          <title>Area of Index Lesions Throughout the Study</title>
          <description>Area (mm^2) of index lesion on Days 0, 20, 28, 42, and 98.</description>
          <population>modified intent to treat (mITT). Baseline for this outcome measure does not include one subject (1 index lesion) who withdrew on Day 18.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Index lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" spread="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393" spread="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" spread="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Index Lesions With Reepithelialization Throughout the Study</title>
        <description>Number of index lesions with 100% reepithelialization on Days 28 and 42.</description>
        <time_frame>Measured at day 28 and 42</time_frame>
        <population>modified intent to treat (mITT). This outcome measure does not include one subject (2 lesions) who withdrew on Day 18.</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396 Topical Cream</title>
            <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Index Lesions With Reepithelialization Throughout the Study</title>
          <description>Number of index lesions with 100% reepithelialization on Days 28 and 42.</description>
          <population>modified intent to treat (mITT). This outcome measure does not include one subject (2 lesions) who withdrew on Day 18.</population>
          <units>lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Index lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area of All Ulcerated Lesions Throughout the Study</title>
        <description>Area of all ulcerated lesions on Days 20, 28, 42, and 98.</description>
        <time_frame>Measured at day 20, 28, 42 and 98</time_frame>
        <population>modified intent to treat (mITT). Baseline for this outcome measure does not include one subject (2 lesions) who withdrew on Day 18.</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396 Topical Cream</title>
            <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
          </group>
        </group_list>
        <measure>
          <title>Area of All Ulcerated Lesions Throughout the Study</title>
          <description>Area of all ulcerated lesions on Days 20, 28, 42, and 98.</description>
          <population>modified intent to treat (mITT). Baseline for this outcome measure does not include one subject (2 lesions) who withdrew on Day 18.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" spread="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Ulcerated Lesions With Reepithelialization on Day 28</title>
        <description>Final cure rate for all ulcerated lesions (100% reepithelialization for ulcerative lesions) on Day 28</description>
        <time_frame>Measured on day 28</time_frame>
        <population>modified intent to treat (mITT). This outcome measure does not include one subject (2 lesions) who withdrew on Day 18.</population>
        <group_list>
          <group group_id="O1">
            <title>WR 279,396 Topical Cream</title>
            <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Ulcerated Lesions With Reepithelialization on Day 28</title>
          <description>Final cure rate for all ulcerated lesions (100% reepithelialization for ulcerative lesions) on Day 28</description>
          <population>modified intent to treat (mITT). This outcome measure does not include one subject (2 lesions) who withdrew on Day 18.</population>
          <units>lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>98 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>WR 279,396 Topical Cream</title>
          <description>WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotrasnsferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was closed prematurely due study team and travel restrictions but not due to any safety issues with the study subjects. Only a total of 50 of the 110 planned subjects were enrolled in the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Afif Ben Salah, MD, PhD</name_or_title>
      <organization>Institut Pasteur of Tunis</organization>
      <phone>011-216-71-792-429</phone>
      <email>afif.bensalah@pasteur.rns.tn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

